Current disease modifying approaches to treat Parkinson’s disease
- 30 November 2015
- journal article
- review article
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 73 (7) , 1365-1379
Abstract
Parkinson’s disease (PD is a progressive neurological disorder characterized by the degeneration and death of midbrain dopamine and non-dopamine neurons in the brain leading to motor dysfunctions and other symptoms, which seriously influence the quality of life of PD patients. The drug L-dopa can alleviate the motor symptoms in PD, but so far there are no rational therapies targeting the underlying neurodegenerative processes. Despite intensive research, the molecular mechanisms causing neuronal loss are not fully understood which has hampered the development of new drugs and disease-modifying therapies. Neurotrophic factors are by virtue of their survival promoting activities attract candidates to counteract and possibly halt cell degeneration in PD. In particular, studies employing glial cell line-derived neurotrophic factor (GDNF) and its family member neurturin (NRTN), as well as the recently described cerebral dopamine neurotrophic factor (CDNF) and the mesencephalic astrocyte-derived neurotrophic factor (MANF) have shown positive results in protecting and repairing dopaminergic neurons in various models of PD. Other substances with trophic actions in dopaminergic neurons include neuropeptides and small compounds that target different pathways impaired in PD, such as increased cell stress, protein handling defects, dysfunctional mitochondria and neuroinflammation. In this review, we will highlight the recent developments in this field with a focus on trophic factors and substances having the potential to beneficially influence the viability and functions of dopaminergic neurons as shown in preclinical or in animal models of PD.Keywords
Funding Information
- Suomen Akatemia
- Jane ja Aatos Erkon Säätiö
- Michael J. Fox Foundation for Parkinson's Research
- Finnish Parkinson Foundation
This publication has 131 references indexed in Scilit:
- Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-κB pathwayCell Death & Disease, 2013
- TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicityProceedings of the National Academy of Sciences, 2013
- Glucocerebrosidase deficiency in substantia nigra of parkinson disease brainsAnnals of Neurology, 2012
- Mitochondrial quality control: a matter of life and death for neuronsThe EMBO Journal, 2012
- α-Synuclein Delays Endoplasmic Reticulum (ER)-to-Golgi Transport in Mammalian Cells by Antagonizing ER/Golgi SNAREsMolecular Biology of the Cell, 2010
- Urate as a Predictor of the Rate of Clinical Decline in Parkinson DiseaseArchives of Neurology, 2009
- MAM: more than just a housekeeperTrends in Cell Biology, 2009
- GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and ParkinsonismProceedings of the National Academy of Sciences, 2009
- The fasting polypeptide FGF21 can enter brain from bloodPeptides, 2007
- Plasma Urate and Risk of Parkinson's DiseaseAmerican Journal of Epidemiology, 2007